Published in Gynecol Oncol on June 01, 2004
Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev (2009) 0.89
An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer (2009) 0.87
eNOS Genetic Polymorphisms and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer. Medicine (Baltimore) (2015) 0.83
Association of endothelial nitric oxide synthase gene polymorphisms with endometrial carcinoma: a preliminary study. J Turk Ger Gynecol Assoc (2011) 0.78
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol (2011) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Drug therapy of urinary urge incontinence: a systematic review. Obstet Gynecol (2002) 1.63
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat (2009) 1.61
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med (2009) 1.51
Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol (2004) 1.46
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat (2006) 1.46
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol (2006) 1.42
To butterfly or to needle: the pilot phase. Ann Intern Med (2004) 1.40
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer (2009) 1.33
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer (2005) 1.27
Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res (2009) 1.26
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res (2007) 1.26
Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res (2006) 1.24
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res (2005) 1.23
The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat (2007) 1.23
Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res (2007) 1.20
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res (2005) 1.13
Novel diamide insecticides: sulfoximines, sulfonimidamides and other new sulfonimidoyl derivatives. Bioorg Med Chem Lett (2012) 1.13
Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost (2003) 1.13
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res (2004) 1.12
Characterization of benign and malignant breast lesions with computed tomography laser mammography (CTLM): initial experience. Invest Radiol (2005) 1.10
Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep (2007) 1.09
Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology (2006) 1.09
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res (2005) 1.07
The C677T polymorphism of the methylenetetrahydrofolate reductase gene and idiopathic recurrent miscarriage. Obstet Gynecol (2002) 1.07
C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol (2007) 1.07
CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat (2004) 1.06
Increased expression of matrix metalloproteinase 2 in uterosacral ligaments is associated with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.06
Uterosacral ligament in postmenopausal women with or without pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumour Biol (2003) 1.04
Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol (2012) 1.03
An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res (2003) 1.02
A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther (2011) 1.01
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol (2007) 1.00
Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol (2009) 1.00
Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer (2004) 0.99
Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res (2002) 0.99
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol (2003) 0.99
Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. Gynecol Oncol (2011) 0.99
Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett (2010) 0.99
Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer (2012) 0.99
Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother (2011) 0.99
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. Clin Cancer Res (2006) 0.98
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep (2005) 0.98
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer (2012) 0.98
Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom (2010) 0.98
Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep (2004) 0.97
Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol (2007) 0.96
Oncogenic BARD1 isoforms expressed in gynecological cancers. Cancer Res (2007) 0.95
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol (2012) 0.95
Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn (2009) 0.95
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci (2012) 0.94
Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res (2010) 0.93
HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep (2005) 0.93
The perioperative morbidity of laparoscopic pelvic lymph node staging in patients with advanced cervical cancer. Anticancer Res (2008) 0.93
Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol (2002) 0.93
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer (2010) 0.93
Phytoestrogens in clinical practice: a review of the literature. Fertil Steril (2007) 0.93
Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer (2002) 0.92
Methylenetetrahydrofolate reductase C677T polymorphism and pregnancy complications. Obstet Gynecol (2007) 0.92